Melanotan II for Tanning & Skin Pigmentation

Candidate profile

Individuals with fair skin (Fitzpatrick type I-III) seeking enhanced skin pigmentation for cosmetic purposes — a darker, tanned appearance without the UV exposure required to achieve it naturally. Melanotan II is the most widely used tanning peptide globally, but it carries a substantially different risk profile than its selective counterpart Melanotan I (afamelanotide).

Typical candidates include:

• Fitzpatrick type I-II individuals (pale skin, burns easily) who desire a tanned appearance but cannot tan naturally or only tan with significant UV exposure and burn risk
• Individuals who want to maintain year-round pigmentation without UV tanning bed use or prolonged sun exposure
• Bodybuilding and fitness competitors seeking enhanced skin color for competition aesthetics
• Fair-skinned individuals who have experienced repeated sunburns and want an alternative approach to achieving pigmentation

Important baseline requirements before considering Melanotan II:

• Dermatological assessment including full-body mole mapping (photographic documentation of all existing nevi) — this is essential, not optional
• No personal history of melanoma or atypical mole syndrome (dysplastic nevus syndrome)
• Understanding that Melanotan II is not approved by any regulatory agency for cosmetic tanning and carries unique risks that Melanotan I does not

Critical distinction from Melanotan I: Melanotan II is a non-selective melanocortin receptor agonist that activates MC1R, MC3R, MC4R, and MC5R. This broad receptor activation produces multiple effects beyond tanning: sexual arousal (MC4R), appetite suppression (MC4R), nausea, facial flushing, and potentially spontaneous penile erection in males. Melanotan I (afamelanotide) selectively activates MC1R and produces pigmentation with a much narrower side-effect profile. The choice between the two compounds should be made with full awareness of this pharmacological difference.

Approach

Subcutaneous Melanotan II administration to stimulate melanogenesis (melanin production) in epidermal melanocytes through MC1R agonism. The tanning mechanism is identical in principle to Melanotan I: MC1R activation on melanocytes upregulates tyrosinase — the rate-limiting enzyme in melanin synthesis — leading to increased eumelanin (brown-black pigment) production and transfer to surrounding keratinocytes.

However, Melanotan II's non-selective receptor binding produces several concurrent pharmacological effects:

• MC1R (melanocytes): Melanogenesis — the desired tanning effect
• MC3R (hypothalamus, gut): Energy homeostasis modulation, reduced appetite in some individuals
• MC4R (hypothalamus, spinal cord, periphery): Sexual arousal and erectile function. MC4R activation in the paraventricular nucleus and spinal cord produces pro-sexual effects — this is the same pathway exploited by PT-141 (bremelanotide), which is a closely related MC4R agonist approved for hypoactive sexual desire disorder
• MC5R (exocrine glands): Sebaceous gland modulation. May affect skin oiliness

The non-selectivity is the fundamental trade-off of Melanotan II: it produces faster and more intense tanning than Melanotan I, but with a wider range of systemic effects. Some users consider the sexual enhancement a benefit; others find it disruptive.

Protocol design

Peptide: Melanotan II (MT-II)

Route: Subcutaneous injection (abdominal preferred)

Starting dose: 100-250 mcg per injection

Loading phase dose: 250-500 mcg per injection

Frequency: Once daily during loading, every other day or less during maintenance

Low-dose titration protocol (recommended for safety):

• Day 1-3: 100 mcg per injection, once daily. Assess tolerance — nausea, flushing, and other side effects should be evaluated at this dose before escalation.
• Day 4-7: 250 mcg per injection, once daily, if the 100 mcg dose was tolerated. This is the standard loading dose for most individuals.
• Week 2-4 (loading): 250-500 mcg once daily or every other day, combined with moderate UV exposure (10-20 minutes, 2-3 times per week). UV exposure is not strictly required for melanogenesis but significantly accelerates the visible tanning response by stimulating melanin transfer to keratinocytes.
• Maintenance (week 5+): 250 mcg once or twice weekly to maintain achieved pigmentation. Some individuals require less frequent dosing (once weekly or less) once target pigmentation is reached.

UV exposure during protocol:

• Low-moderate UV exposure enhances and accelerates the tanning response
• This does NOT mean deliberate sunburning — controlled exposure (10-20 minutes of natural sunlight or low-dose UV bed) is sufficient
• The combination of Melanotan II + moderate UV produces a synergistic tanning effect — the peptide provides the melanin synthesis substrate, UV exposure triggers melanin transfer and distribution
• Sunscreen should be used for prolonged UV exposure even while using Melanotan II — increased melanin provides modest UV protection (SPF 3-4 equivalent) but does not eliminate burn risk

Timing of injection: Many users inject in the evening or before bed to sleep through the acute side effects (nausea, facial flushing), which typically peak 30-60 minutes after injection and resolve within 1-2 hours.

Reconstitution: Reconstitute with bacteriostatic water. Typical reconstitution: 1 mL to a 10 mg vial = 10 mg/mL = 10,000 mcg/mL. A 250 mcg dose = 0.025 mL (2.5 units on an insulin syringe). Precise low-volume dosing with insulin syringes is essential.

Storage: Refrigerate at 2-8 degrees C. Use within 4 weeks. Protect from light.

Expected timeline

Days 1-3 (initial dosing): No pigmentation change. Side effects are the primary experience during this period: nausea (most common, 70-80% of users), facial flushing (30-50 minutes post-injection), decreased appetite, and in males, spontaneous erection (30-60 minutes post-injection). These effects diminish with repeated dosing as tolerance develops.

Days 4-10: Existing moles, freckles, and areas of pre-existing pigmentation darken first. This occurs because melanocytes in these areas have higher baseline tyrosinase activity and respond to MC1R stimulation more rapidly. This is an expected but important finding — it is one reason why baseline mole mapping is essential (to distinguish expected darkening from pathological change).

Weeks 2-3: Visible tanning of general skin becomes apparent, particularly if combined with UV exposure. The tan appears gradually and evenly in sun-exposed areas. Areas with less UV exposure may tan more slowly. Fitzpatrick type I individuals may progress to a type II-III appearance; type II individuals may reach type III-IV.

Weeks 4-6: Target pigmentation is typically achieved during this window. The tan is eumelanin-dominant and appears natural — a warm, brown tone rather than the orange tone produced by dihydroxyacetone (DHA) self-tanners. Maintenance dosing begins once the desired pigmentation level is reached.

Maintenance phase: Pigmentation is maintained with weekly or biweekly injections. Melanin has a half-life of approximately 2-3 weeks in the epidermis (tied to keratinocyte turnover), so discontinuation results in gradual fading over 4-8 weeks. Complete return to baseline pigmentation typically occurs within 2-3 months of discontinuation.

Complementary peptides

• Melanotan I (afamelanotide): The selective alternative. Some protocols transition from Melanotan II (for initial pigmentation loading due to its potency) to Melanotan I (for maintenance, due to its cleaner side effect profile). This leverages MT-II's faster onset while avoiding chronic exposure to its non-selective effects.
• PT-141 (bremelanotide): If the sexual enhancement effect of Melanotan II is desired but the tanning effect is not (or vice versa), PT-141 provides MC4R agonism for sexual function without significant MC1R tanning effect. Using PT-141 separately allows dosing the sexual and tanning effects independently.
• GHK-Cu (topical): Copper peptide that supports skin quality and repair. If UV exposure during the Melanotan II protocol causes any UV damage, topical GHK-Cu supports dermal repair and collagen maintenance.

Evidence assessment

Melanotan II was developed at the University of Arizona in the 1990s as a tanning agent for UV protection research. The pharmacology is well-characterized: MC1R-mediated melanogenesis, receptor binding profiles across all melanocortin receptors, and the dose-response relationship for tanning are documented in published research.

Clinical trial data is limited. Melanotan II was studied in early-phase human trials that confirmed its melanogenic efficacy and documented its side effect profile (nausea, flushing, sexual effects). However, it was never pursued through full regulatory development for tanning — the non-selective receptor profile and side effects made it an unsuitable drug candidate when Melanotan I (selective for MC1R) was available as an alternative. Melanotan I (as afamelanotide/Scenesse) completed the regulatory pathway and received EMA approval for erythropoietic protoporphyria.

The widespread use of Melanotan II as an unregulated tanning peptide has produced a large body of user experience data and case reports, including reports of adverse effects (nevi changes, new mole formation, rhabdomyolysis in one case). However, this is observational, uncontrolled data with inherent selection and reporting bias.

The evidence for melanogenic efficacy is strong (well-characterized pharmacology, confirmed in human studies). The evidence for long-term safety is weak (no controlled long-term studies, reliance on uncontrolled user reports and case series).

Monitoring markers

• Full-body mole mapping (dermatoscopic photography): mandatory at baseline, and repeated at week 6 and every 3 months during ongoing use. This is the single most important monitoring measure. Any new moles, changes in existing moles (size, shape, border irregularity, color change), or atypical-appearing nevi require immediate dermatological evaluation.
• Skin pigmentation assessment: visual and/or melanin index measurement at baseline, week 3, and week 6
• Blood pressure: baseline and week 4. Melanocortin receptor activation can produce modest cardiovascular effects
• Liver function (ALT, AST): baseline and after the loading phase (week 4-6)
• Renal function: baseline
• Side effect diary: document nausea severity, flushing duration, appetite changes, and sexual effects for the first 2 weeks to establish individual tolerance profile
• Mole self-examination: monthly ABCDE assessment (Asymmetry, Border, Color, Diameter, Evolution) of all nevi

Assessment schedule:

• Baseline: dermatological full-body exam with dermatoscopy and photographic mole mapping, baseline bloodwork
• Week 3: pigmentation check, side effect assessment
• Week 6: dermatological follow-up with mole comparison to baseline
• Every 3 months during ongoing use: dermatological follow-up
• 3 months post-discontinuation: final dermatological assessment

Limitations and considerations

• Nevi changes are the primary dermatological concern: Multiple case reports document new mole formation and changes in existing moles during Melanotan II use. While melanocyte activation per se does not cause melanoma, increased melanocyte proliferative signaling in individuals with pre-existing atypical nevi raises legitimate concern. Dermatological surveillance is essential and non-negotiable.
• No regulatory approval anywhere: Unlike Melanotan I (EMA-approved as Scenesse), Melanotan II is not approved by any regulatory agency for any indication. All use is unregulated.
• Non-selective receptor activation produces unavoidable off-target effects: Nausea, facial flushing, appetite suppression, and sexual effects are intrinsic to the pharmacology, not impurities or dose errors. These effects cannot be eliminated — only mitigated through low-dose protocols and tolerance development.
• Sexual effects can be disruptive: In males, spontaneous erections 30-60 minutes post-injection are common, particularly at higher doses. This side effect is pharmacological (MC4R-mediated) and expected. In females, increased sexual desire and genital arousal are reported. These effects may be unwelcome depending on the timing and context of injection.
• Peptide source quality: As an unregulated compound, Melanotan II quality varies dramatically between sources. Contaminated, mislabeled, or degraded product is a real risk. Third-party testing (HPLC, endotoxin) is strongly advisable.
• Uneven pigmentation: Some individuals develop uneven tanning — freckles may darken disproportionately, and areas with different melanocyte density may tan unevenly. Individuals with melasma may experience worsening of existing hyperpigmentation.
• Nausea management: For many users, nausea is the dose-limiting side effect. Strategies include: injecting before bed, starting at very low doses (100 mcg), using antiemetics (ginger, ondansetron) if severe, and avoiding injection on a full stomach.
• Cardiovascular considerations: Melanocortin peptides can increase blood pressure through central sympathetic activation. Individuals with hypertension should monitor blood pressure during the loading phase.
• Prolonged erection risk (priapism): Rare but reported — sustained erection lasting more than 4 hours requires medical attention. This is an MC4R-mediated effect and constitutes a medical emergency if it occurs.
• Children, adolescents, pregnancy: Absolute contraindications. No safety data exists for these populations. Melanocortin receptor activation during development could have unpredictable effects.
• Interaction with UV-sensitizing medications: Tetracycline antibiotics, fluoroquinolones, thiazide diuretics, and other photosensitizing drugs increase UV damage risk. If combining Melanotan II with UV exposure while taking photosensitizing medications, the sunburn risk is amplified.
• Cosmetic expectations vs. reality: Melanotan II produces a natural-looking eumelanin tan, but the shade and intensity are genetically limited. Individuals with MC1R loss-of-function variants (common in red-haired, Fitzpatrick I individuals) may have a blunted response. The tan will never exceed the individual's genetic pigmentation ceiling.
• Legal status: Melanotan II is a controlled or prescription substance in some jurisdictions (Australia, UK, Denmark). Users should be aware of local regulatory classification.